Profile data is unavailable for this security.
About the company
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
- Revenue in EUR (TTM)42.04bn
- Net income in EUR6.63bn
- Incorporated1994
- Employees95.44k
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Amunix Pharmaceuticals Inc | -1.59% | 1.25bn |
| American Finance Trust Inc-Office Building(3) | -1.58% | 261.00m |
| ORIGIMM Biotechnology GmbH | 1.98% | -- |
| Kadmon Holdings Inc | -1.64% | 1.76bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 6.06bn | 941.07m | 43.00bn | 17.15k | 46.66 | 4.22 | 29.49 | 7.25 | 12.21 | 41.87 | 78.57 | 134.94 | 0.3667 | -- | -- | 360,648.70 | 5.72 | 5.00 | 7.01 | 6.14 | 38.69 | 39.82 | 15.59 | 13.97 | -- | 12.82 | 0.1924 | 31.40 | 19.99 | 5.53 | -7.67 | 17.49 | 29.66 | 3.33 |
| GSK plc | 38.69bn | 4.65bn | 79.20bn | 90.10k | 14.16 | 3.09 | 8.44 | 1.93 | 1.10 | 1.29 | 9.00 | 5.03 | 0.3941 | 2.06 | 4.90 | 363,201.50 | 5.80 | 6.96 | 10.20 | 11.61 | 65.40 | 68.48 | 14.71 | 14.68 | 1.31 | 10.40 | 0.4941 | 94.85 | 0.044 | 4.11 | -23.73 | 36.90 | 4.50 | -4.36 |
| Sanofi SA | 42.04bn | 6.63bn | 121.02bn | 95.44k | 16.63 | 1.55 | 13.29 | 2.64 | 5.27 | 5.27 | 33.50 | 56.67 | 0.3591 | 1.38 | 5.73 | 440,466.50 | 5.68 | 5.19 | 6.91 | 6.23 | 69.45 | 68.06 | 15.82 | 15.36 | 0.861 | 32.43 | 0.2311 | 66.94 | 4.83 | 2.46 | -49.38 | 7.20 | -0.387 | 2.28 |
| Novo Nordisk A/S | 21.15bn | 6.80bn | 179.60bn | 50.82k | 35.47 | 23.59 | 24.09 | 8.66 | 22.04 | 22.04 | 68.54 | 33.15 | 0.8342 | 1.25 | 4.70 | 3,290,321.00 | 26.81 | 32.65 | 51.95 | 63.12 | 83.92 | 83.79 | 32.14 | 33.52 | 0.7412 | 19.08 | 0.2546 | 50.18 | 10.91 | 4.72 | 13.33 | 4.72 | -2.23 | 6.47 |
| AstraZeneca plc | 42.60bn | -1.21bn | 198.58bn | 83.10k | -- | 5.64 | 31.65 | 4.60 | -0.6954 | -0.6954 | 23.37 | 18.97 | 0.5174 | 2.02 | 5.77 | 433,490.80 | -1.47 | 2.62 | -1.98 | 3.66 | 74.85 | 78.90 | -2.84 | 6.61 | 0.6737 | 5.85 | 0.451 | 196.26 | 40.58 | 10.22 | -96.50 | -49.76 | -1.01 | 1.03 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 16 Jun 2022 | 62.74m | 4.95% |
| The Vanguard Group, Inc.as of 05 Aug 2022 | 29.96m | 2.36% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 25.53m | 2.01% |
| BlackRock Fund Advisorsas of 03 Aug 2022 | 20.81m | 1.64% |
| FIL Investment Advisors (UK) Ltd.as of 31 May 2022 | 13.76m | 1.09% |
| BlackRock Advisors (UK) Ltd.as of 04 Aug 2022 | 11.34m | 0.90% |
| Lyxor International Asset Management SASas of 02 Aug 2022 | 11.32m | 0.89% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 10.71m | 0.85% |
| Amundi Asset Management SA (Investment Management)as of 02 Aug 2022 | 9.37m | 0.74% |
| BlackRock Investment Management (UK) Ltd.as of 11 Aug 2022 | 9.17m | 0.72% |
